PreprintArticleVersion 1Preserved in Portico This version is not peer-reviewed
Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy
Version 1
: Received: 7 August 2020 / Approved: 9 August 2020 / Online: 9 August 2020 (15:34:00 CEST)
How to cite:
Sung, P. S.; Choi, M. H.; Yang, H.; Lee, S. K.; Chun, H. J.; Jang, J. W.; Choi, J. Y.; Yoon, S. K.; Choi, J.-I.; Lee, Y. J.; Bae, S. H. Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Preprints2020, 2020080218. https://doi.org/10.20944/preprints202008.0218.v1
Sung, P. S.; Choi, M. H.; Yang, H.; Lee, S. K.; Chun, H. J.; Jang, J. W.; Choi, J. Y.; Yoon, S. K.; Choi, J.-I.; Lee, Y. J.; Bae, S. H. Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Preprints 2020, 2020080218. https://doi.org/10.20944/preprints202008.0218.v1
Sung, P. S.; Choi, M. H.; Yang, H.; Lee, S. K.; Chun, H. J.; Jang, J. W.; Choi, J. Y.; Yoon, S. K.; Choi, J.-I.; Lee, Y. J.; Bae, S. H. Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Preprints2020, 2020080218. https://doi.org/10.20944/preprints202008.0218.v1
APA Style
Sung, P. S., Choi, M. H., Yang, H., Lee, S. K., Chun, H. J., Jang, J. W., Choi, J. Y., Yoon, S. K., Choi, J. I., Lee, Y. J., & Bae, S. H. (2020). Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy. Preprints. https://doi.org/10.20944/preprints202008.0218.v1
Chicago/Turabian Style
Sung, P. S., Young Joon Lee and Si Hyun Bae. 2020 "Diffusion-Weighted Magnetic Resonance Imaging in Hepatocellular Carcinoma as a Predictor of a Response to Cisplatin-Based Hepatic Arterial Infusion Chemotherapy" Preprints. https://doi.org/10.20944/preprints202008.0218.v1
Abstract
This study aimed to identify the utility of diffusion-weighted magnetic resonance (MR) imaging with an apparent diffusion coefficient (ADC) map as a predictor of the intrahepatic response of hepatocellular carcinoma (HCC) to cisplatin-based hepatic arterial infusion chemotherapy (HAIC). We retrospectively evaluated 113 consecutive patients with HCC who underwent gadoxetic acid-enhanced and diffusion-weighted MR imaging. The appropriate cutoff for the tumor-to-liver ADC ratio was determined to be 0.741. Of the 113 patients, 51 (45%) presented with a tumor-to-liver ADC ratio < 0.741. Evaluation of the intrahepatic treatment response after 2-3 cycles of HAIC in these 51 patients revealed that 20 patients (39%) experienced an objective response to HAIC. On the other hand, only 10 of the 62 patients with a tumor-to-liver ADC ratio ≥ 0.741 (16%) experienced an objective response. Thus, the objective response rate was significantly higher in patients with a tumor-to-liver ADC ratio < 0.741 than in those with a tumor-to-liver ADC ratio ≥ 0.741 (P = 0.006). Multivariate logistic regression analysis using parameters including perfusion alteration, percentage of a non-enhancing portion, and tumor-to-liver ADC ratio revealed that a tumor-to-liver ADC ratio < 0.741 (odds ratio 3.03; P = 0.015) is the sole predictor of an objective response to HAIC. Overall survival rates were significantly higher in patients with objective responses to HAIC than in those without objective responses (P = 0.001 by log-rank test). In conclusion, patients with unresectable HCC with a tumor-to-liver ADC ratio < 0.741 showed a favorable intrahepatic response to HAIC. Therefore, diffusion-weighted MR imaging can play a critical role as a predictor of response to cisplatin-based HAIC in unresectable HCC.
Keywords
hepatocellular carcinoma; diffusion-weighted imaging; magnetic resonance; hepatic arterial infusion chemotherapy
Subject
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.